Opportunity Information: Apply for PA 21 164
The Agency for Health Care Research and Quality (AHRQ) is offering a discretionary grant opportunity titled "Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)" (Funding Opportunity Number: PA-21-164; CFDA/Assistance Listing: 93.226). The focus of this funding announcement is on research projects that test promising digital healthcare interventions designed to improve the quality of care and the delivery of healthcare services where care actually happens, meaning at the point of care in real-world clinical workflows. In practical terms, applicants are expected to propose and study technology-enabled approaches (for example, digital tools, software-driven interventions, and related healthcare IT solutions) that can measurably strengthen care processes, decision-making, coordination, safety, efficiency, or patient-centeredness during clinical encounters or within frontline care delivery settings.
This opportunity uses the Phased Innovation Award mechanism (R21/R33), which is structured to support projects that need an initial period of development and refinement before scaling into a broader, more robust phase of implementation and evaluation. The R21 phase can provide up to two years of support and is intended for early-stage developmental work, such as adapting a digital intervention for a clinical environment, building or improving key functions, testing feasibility, addressing usability and workflow fit, and generating the early evidence needed to justify expansion. If predefined milestones are met, the project can transition to the R33 phase, which can provide up to three additional years for expanded activities. The R33 phase is generally where applicants would conduct larger-scale testing or more rigorous evaluation in real care settings, examine implementation and sustainability, and produce stronger evidence about effectiveness and impact on healthcare quality at the point of care. Clinical trials are optional under this announcement, so applicants may propose study designs that include a trial, but they are not required to do so as long as the approach appropriately tests the digital intervention and its impact.
A wide range of organizations are eligible to apply. Eligible applicants include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities and Indian housing authorities; and nonprofit organizations, including both 501(c)(3) nonprofits and nonprofits without 501(c)(3) status (in both cases, other than institutions of higher education). The announcement also highlights additional eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal government agencies; regional organizations; and U.S. territories or possessions. At the same time, it clearly states that non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible.
Key administrative details included in the listing are that the funding instrument is a grant and the funding activity category is health. The original closing date shown for this opportunity is July 17, 2024, and the funding announcement record indicates a creation date of February 9, 2021. The public summary does not specify an award ceiling or the expected number of awards in the provided fields, so applicants would typically confirm the most current budget guidance, limits, and anticipated award volume in the full funding opportunity announcement and any related notices.Apply for PA 21 164
- The Agency for Health Care Research and Quality in the health sector is offering a public funding opportunity titled "Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.226.
- This funding opportunity was created on 2021-02-09.
- Applicants must submit their applications by 2024-07-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the name of this grant opportunity?
The grant opportunity is titled "Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)."
Which agency is offering this funding?
The Agency for Health Care Research and Quality (AHRQ) is offering this discretionary grant opportunity.
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PA-21-164.
What is the CFDA/Assistance Listing number?
The CFDA/Assistance Listing number is 93.226.
What kind of projects is AHRQ looking to fund under this announcement?
AHRQ is seeking research projects that test promising digital healthcare interventions designed to improve the quality of care and the delivery of healthcare services where care actually happens: at the point of care, within real-world clinical workflows and frontline care delivery settings.
What does "point of care" mean in this funding announcement?
In this announcement, "point of care" refers to real-world clinical encounters and frontline care settings where clinicians and care teams deliver care and make decisions as part of routine workflows.
What types of interventions are in scope?
Technology-enabled approaches are in scope, including digital tools, software-driven interventions, and related healthcare IT solutions, as long as they are designed to measurably improve care quality during clinical workflows.
What outcomes or improvements should the digital solutions target?
The opportunity emphasizes improvements to care processes and the delivery of healthcare services at the point of care. Examples of targeted improvements described include strengthening decision-making, coordination, safety, efficiency, and patient-centeredness during clinical encounters or within frontline care delivery settings.
What grant mechanism is being used?
This opportunity uses the Phased Innovation Award mechanism (R21/R33).
How does the R21/R33 phased structure work?
The mechanism supports projects that need an initial period of development and refinement (R21) before expanding into a broader phase of implementation and evaluation (R33). Transition from R21 to R33 depends on meeting predefined milestones.
How long can the R21 phase last and what is it intended to support?
The R21 phase can provide up to two years of support and is intended for early-stage developmental work such as adapting a digital intervention for a clinical environment, building or improving key functions, testing feasibility, addressing usability and workflow fit, and generating early evidence needed to justify expansion.
How long can the R33 phase last and what is it intended to support?
The R33 phase can provide up to three additional years and is generally intended for larger-scale testing or more rigorous evaluation in real care settings, examining implementation and sustainability, and producing stronger evidence about effectiveness and impact on healthcare quality at the point of care.
What determines whether a project can move from R21 to R33?
Progression from the R21 phase to the R33 phase is based on meeting predefined milestones.
Are clinical trials required?
No. Clinical trials are optional under this announcement. Applicants may propose designs that include a trial, but they are not required to do so as long as the approach appropriately tests the digital intervention and its impact.
What is the funding instrument?
The funding instrument is a grant.
What is the funding activity category?
The funding activity category is health.
Which organizations are eligible to apply?
A wide range of U.S.-based organizations are eligible, including state, county, city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; Native American tribal organizations other than federally recognized tribal governments; public housing authorities and Indian housing authorities; and nonprofit organizations (both 501(c)(3) and non-501(c)(3), in both cases other than institutions of higher education).
Are community-based or faith-based organizations eligible?
Yes. The announcement explicitly includes faith-based or community-based organizations as eligible applicant types.
Are minority-serving institutions highlighted as eligible applicants?
Yes. The announcement highlights eligibility for Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); and other listed categories.
Are U.S. territories eligible to apply?
Yes. U.S. territories or possessions are listed as eligible applicant types.
Are any federal entities eligible?
Yes. The announcement includes eligible federal government agencies as eligible applicant types.
Are foreign (non-U.S.) organizations eligible to apply?
No. Non-domestic (non-U.S.) entities (foreign institutions) are not eligible to apply.
Can a U.S. organization include a non-U.S. component in the project?
No. Non-domestic components of U.S. organizations are also not eligible under this announcement.
What is the closing date shown for this opportunity?
The original closing date shown is July 17, 2024.
When was the funding announcement record created?
The record indicates a creation date of February 9, 2021.
Does the public summary specify an award ceiling?
No. The provided fields in the public summary do not specify an award ceiling.
Does the public summary specify the expected number of awards?
No. The provided fields do not list the expected number of awards.
Where should applicants look for the most current budget guidance and any limits?
Because the public summary does not include the award ceiling or expected number of awards, applicants would typically confirm the most current budget guidance, limits, and anticipated award volume in the full funding opportunity announcement and any related notices.
Browse more opportunities from the same category: Health
Next opportunity: Understanding U.S. Foreign Policy and U.S.-India Relations
Previous opportunity: Department of the Interior - Bureau of Land Management ORWA Cultural and Paleontological Resource Management
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 21 164
Applicants also applied for:
Applicants who have applied for this opportunity (PA 21 164) also looked into and applied for these:
| Funding Opportunity |
|---|
| NEI Translational Research Program (TRP) on Therapy for Visual Disorders (R24 Clinical Trial Optional) Apply for PAR 20 319 Funding Number: PAR 20 319 Agency: National Institutes of Health Category: Health Funding Amount: $15,000,000 |
| Basic Research to Inform Vaccine and Therapeutic Development for Non-Polio Human Enteroviruses (NPEV) (R01 Clinical Trial Not Allowed) Apply for RFA AI 21 006 Funding Number: RFA AI 21 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tobacco Regulatory Science (R01 Clinical Trial Optional) Apply for RFA OD 21 002 Funding Number: RFA OD 21 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Frontier Health Markets APS Apply for 7200AA21APS00005 Funding Number: 7200AA21APS00005 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| Fogarty Global Trauma and Injury Research Training Program (D43 Clinical Trial Optional) Apply for RFA TW 21 003 Funding Number: RFA TW 21 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global Infectious Disease Research Training Program (D43 Clinical Trial Optional) Apply for PAR 21 120 Funding Number: PAR 21 120 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34 - Clinical Trial Not Allowed) Apply for PAR 21 146 Funding Number: PAR 21 146 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovation for Tuberculosis Vaccine Discovery (ITVD) (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 21 007 Funding Number: RFA AI 21 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Facility and Building System Upgrades Support for the Regional Biocontainment Laboratories (G20 Clinical Trial Not Allowed) Apply for RFA AI 21 022 Funding Number: RFA AI 21 022 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early Intervention to Promote Cardiovascular Health of Mothers and Children (ENRICH) Multisite Clinical Centers (Collaborative UG3/UH3 Clinical Trial Required) Apply for RFA HL 22 007 Funding Number: RFA HL 22 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Maximizing Access to Research Careers (T34 - Clinical Trial Not Allowed) Apply for PAR 21 147 Funding Number: PAR 21 147 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mental Health Research Awards for Investigators Early in their Career in Low and Middle-Income Countries (R01 Clinical Trial Optional) Apply for RFA MH 21 120 Funding Number: RFA MH 21 120 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| NINDS Institutional Research Training Program (T32 - Clinical Trial Not Allowed) Apply for PAR 21 149 Funding Number: PAR 21 149 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Lung Transplant Consortium - Clinical Centers (U01 - Clinical Trial Not Allowed) Apply for RFA HL 22 002 Funding Number: RFA HL 22 002 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Lung Transplant Consortium - Data Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA HL 22 003 Funding Number: RFA HL 22 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The Midlife in the United States Study (U19 Clinical Trial Not Allowed) Apply for PAR 21 156 Funding Number: PAR 21 156 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The Midlife in the United States Study - Cognitive and Neurocognitive Precursors of AD/ADRD (U01 Clinical Trial Not Allowed) Apply for PAR 21 157 Funding Number: PAR 21 157 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Triadic Interactions in Clinical Encounters Involving People with Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional) Apply for RFA AG 22 020 Funding Number: RFA AG 22 020 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required) Apply for PAR 21 133 Funding Number: PAR 21 133 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required) Apply for PAR 21 135 Funding Number: PAR 21 135 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 21 164", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.